Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia

E. Spina, A. Avenoso, G. Facciolà, M. Salemi, M. G. Scordo, M. Ancione, A. G. Madia, E. Perucca

Research output: Contribution to journalArticle

105 Citations (Scopus)

Abstract

Rationale: Evaluation of relationships between serum antipsychotic drug concentrations and clinical response may provide valuable information for rational dosage adjustments. For risperidone, this relationship has been little investigated to date. Objective: To assess the relationship between plasma concentrations of risperidone and its active 9-hydroxy-metabolite (9-OH-risperidone) and clinical response in schizophrenic patients who experienced an acute exacerbation of the disorder. Methods: Forty-two patients (30 males, 12 females, age 24-60 years) were given risperidone at dosages ranging from 4 to 9 mg/day for 6 weeks. The design of the study was open and risperidone dosage could be adjusted individually according to clinical response. Steady-state plasma concentrations of risperidone and its 9-hydroxymetabolite were measured after 4 and 6 weeks using a specific HPLC assay. Psychopathological state was assessed at baseline and at weeks 2, 4, and 6 by means of the positive and negative syndrome scale (PANSS), and patients were considered responders if they showed a greater than 20% reduction in total PANSS score at final evaluation compared with baseline. Results: Mean plasma concentrations of risperidone, 9-OH-risperidone, and active moiety (sum of risperidone and 9-OH-risperidone concentrations) did not differ between responders (n=28) and non-responders (n=14). No correlation between plasma levels and percent decrease in total PANSS score was found for risperidone (rs=-0.187, NS), 9-OH-risperidone (rs=0.246, NS), and active moiety (rs=0.249, NS). Active moiety concentrations in plasma were higher (P

Original languageEnglish
Pages (from-to)238-243
Number of pages6
JournalPsychopharmacology
Volume153
Issue number2
DOIs
Publication statusPublished - 2001

Fingerprint

Risperidone
Schizophrenia
Paliperidone Palmitate
Social Adjustment
Antipsychotic Agents
High Pressure Liquid Chromatography

Keywords

  • 9-Hydroxy-risperidone
  • Parkinsonism
  • Plasma concentration
  • Risperidone
  • Schizophrenia
  • Therapeutic drug monitoring

ASJC Scopus subject areas

  • Pharmacology

Cite this

Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia. / Spina, E.; Avenoso, A.; Facciolà, G.; Salemi, M.; Scordo, M. G.; Ancione, M.; Madia, A. G.; Perucca, E.

In: Psychopharmacology, Vol. 153, No. 2, 2001, p. 238-243.

Research output: Contribution to journalArticle

Spina, E. ; Avenoso, A. ; Facciolà, G. ; Salemi, M. ; Scordo, M. G. ; Ancione, M. ; Madia, A. G. ; Perucca, E. / Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia. In: Psychopharmacology. 2001 ; Vol. 153, No. 2. pp. 238-243.
@article{90254571be4b4e60a7d845ff7527d8af,
title = "Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia",
abstract = "Rationale: Evaluation of relationships between serum antipsychotic drug concentrations and clinical response may provide valuable information for rational dosage adjustments. For risperidone, this relationship has been little investigated to date. Objective: To assess the relationship between plasma concentrations of risperidone and its active 9-hydroxy-metabolite (9-OH-risperidone) and clinical response in schizophrenic patients who experienced an acute exacerbation of the disorder. Methods: Forty-two patients (30 males, 12 females, age 24-60 years) were given risperidone at dosages ranging from 4 to 9 mg/day for 6 weeks. The design of the study was open and risperidone dosage could be adjusted individually according to clinical response. Steady-state plasma concentrations of risperidone and its 9-hydroxymetabolite were measured after 4 and 6 weeks using a specific HPLC assay. Psychopathological state was assessed at baseline and at weeks 2, 4, and 6 by means of the positive and negative syndrome scale (PANSS), and patients were considered responders if they showed a greater than 20{\%} reduction in total PANSS score at final evaluation compared with baseline. Results: Mean plasma concentrations of risperidone, 9-OH-risperidone, and active moiety (sum of risperidone and 9-OH-risperidone concentrations) did not differ between responders (n=28) and non-responders (n=14). No correlation between plasma levels and percent decrease in total PANSS score was found for risperidone (rs=-0.187, NS), 9-OH-risperidone (rs=0.246, NS), and active moiety (rs=0.249, NS). Active moiety concentrations in plasma were higher (P",
keywords = "9-Hydroxy-risperidone, Parkinsonism, Plasma concentration, Risperidone, Schizophrenia, Therapeutic drug monitoring",
author = "E. Spina and A. Avenoso and G. Facciol{\`a} and M. Salemi and Scordo, {M. G.} and M. Ancione and Madia, {A. G.} and E. Perucca",
year = "2001",
doi = "10.1007/s002130000576",
language = "English",
volume = "153",
pages = "238--243",
journal = "Psychopharmacology",
issn = "0033-3158",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia

AU - Spina, E.

AU - Avenoso, A.

AU - Facciolà, G.

AU - Salemi, M.

AU - Scordo, M. G.

AU - Ancione, M.

AU - Madia, A. G.

AU - Perucca, E.

PY - 2001

Y1 - 2001

N2 - Rationale: Evaluation of relationships between serum antipsychotic drug concentrations and clinical response may provide valuable information for rational dosage adjustments. For risperidone, this relationship has been little investigated to date. Objective: To assess the relationship between plasma concentrations of risperidone and its active 9-hydroxy-metabolite (9-OH-risperidone) and clinical response in schizophrenic patients who experienced an acute exacerbation of the disorder. Methods: Forty-two patients (30 males, 12 females, age 24-60 years) were given risperidone at dosages ranging from 4 to 9 mg/day for 6 weeks. The design of the study was open and risperidone dosage could be adjusted individually according to clinical response. Steady-state plasma concentrations of risperidone and its 9-hydroxymetabolite were measured after 4 and 6 weeks using a specific HPLC assay. Psychopathological state was assessed at baseline and at weeks 2, 4, and 6 by means of the positive and negative syndrome scale (PANSS), and patients were considered responders if they showed a greater than 20% reduction in total PANSS score at final evaluation compared with baseline. Results: Mean plasma concentrations of risperidone, 9-OH-risperidone, and active moiety (sum of risperidone and 9-OH-risperidone concentrations) did not differ between responders (n=28) and non-responders (n=14). No correlation between plasma levels and percent decrease in total PANSS score was found for risperidone (rs=-0.187, NS), 9-OH-risperidone (rs=0.246, NS), and active moiety (rs=0.249, NS). Active moiety concentrations in plasma were higher (P

AB - Rationale: Evaluation of relationships between serum antipsychotic drug concentrations and clinical response may provide valuable information for rational dosage adjustments. For risperidone, this relationship has been little investigated to date. Objective: To assess the relationship between plasma concentrations of risperidone and its active 9-hydroxy-metabolite (9-OH-risperidone) and clinical response in schizophrenic patients who experienced an acute exacerbation of the disorder. Methods: Forty-two patients (30 males, 12 females, age 24-60 years) were given risperidone at dosages ranging from 4 to 9 mg/day for 6 weeks. The design of the study was open and risperidone dosage could be adjusted individually according to clinical response. Steady-state plasma concentrations of risperidone and its 9-hydroxymetabolite were measured after 4 and 6 weeks using a specific HPLC assay. Psychopathological state was assessed at baseline and at weeks 2, 4, and 6 by means of the positive and negative syndrome scale (PANSS), and patients were considered responders if they showed a greater than 20% reduction in total PANSS score at final evaluation compared with baseline. Results: Mean plasma concentrations of risperidone, 9-OH-risperidone, and active moiety (sum of risperidone and 9-OH-risperidone concentrations) did not differ between responders (n=28) and non-responders (n=14). No correlation between plasma levels and percent decrease in total PANSS score was found for risperidone (rs=-0.187, NS), 9-OH-risperidone (rs=0.246, NS), and active moiety (rs=0.249, NS). Active moiety concentrations in plasma were higher (P

KW - 9-Hydroxy-risperidone

KW - Parkinsonism

KW - Plasma concentration

KW - Risperidone

KW - Schizophrenia

KW - Therapeutic drug monitoring

UR - http://www.scopus.com/inward/record.url?scp=0035140878&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035140878&partnerID=8YFLogxK

U2 - 10.1007/s002130000576

DO - 10.1007/s002130000576

M3 - Article

VL - 153

SP - 238

EP - 243

JO - Psychopharmacology

JF - Psychopharmacology

SN - 0033-3158

IS - 2

ER -